Cingulate Announces Successful Transfer of CTx-1301 Proprietary PTR™ Manufacturing Processes to Societal CDMO Scalable Supply of CTx-1301 Ready to be. | May 3, 2023
KANSAS CITY, Kan., April 14, 2023 Cingulate Inc. , a biopharmaceutical company utilizing its proprietary Precision Timed Release™ drug delivery platform technology to build and advance a. | April 14, 2023
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.